Published in Vaccine Weekly, November 6th, 2002
Kei Kawana and colleagues at the University of Tokyo assigned 76 women to one of four categories based upon their cervical pathology, normal (n=7), CIN1 (n=37), CIN2 or CIN3 (n=19), or cervical cancer (n=13). Serum samples from the subjects were tested for neutralizing antibodies against HPV16 using HPV16-pseudovirions.
Women with normal cervical pathology were significantly more likely (p<0.0001) to have HPV16...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly